{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:19:58Z","timestamp":1790363998748,"version":"4.1.0"},"reference-count":28,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,9,1]]},"abstract":"\n Importance<\/jats:title>\n Psoriasis is a chronic inflammatory skin disease with unmet needs for tailored treatment and therapy de-escalation strategies.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate early intervention with and prolonging the dosing interval for guselkumab, a p19 subunit-targeted interleukin (IL)-23 inhibitor, in patients with moderate to severe psoriasis.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The GUIDE clinical trial is an ongoing phase 3b, randomized, double-blinded trial conducted across 80 centers in Germany and France comprising 3 parts evaluating the impact of early disease intervention, prolonged dosing interval, and maintenance of response following treatment withdrawal among adults with moderate to severe plaque psoriasis. In study part 2, reported herein, first and last patient visits were September 2019 and March 2022, respectively.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n \n In GUIDE part 1 (week [W]0-W28), patients received guselkumab, 100 mg, at W0, W4, W12, and W20. Those achieving a Psoriasis Area and Severity Index (PASI) of 0 at both W20 and W28 were termed\n super responders<\/jats:italic>\n (SRes). In part 2 (W28-W68), SRes were randomized to guselkumab, 100 mg, every 8 weeks or every 16 weeks; non-SRes continued open-label guselkumab every 8 weeks.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Primary objective was to demonstrate noninferiority (with a 10% margin) of guselkumab every 16 weeks vs every 8 weeks dosing among SRes for maintenance of disease control (PASI &amp;lt;3 at W68). Biomarker substudies assessed immunologic effects in skin and blood.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Overall, 822 patients received guselkumab in part 2 (297 [36.1%] SRes [every 8 weeks\/every 16 weeks; n\u2009=\u2009148\/n\u2009=\u2009149] and 525 [63.9%] non-SRes). Among SRes, mean (SD) age was 39.4 (14.1) years, 95 (32.0%) were female, and 202 (68.0%) were male. The primary end point of noninferiority for guselkumab every 16 weeks vs every 8 weeks in SRes was met (\n P<\/jats:italic>\n \u2009=\u2009.001), with 91.9% (137\/149; 90% CI, 87.3%-95.3%) of SRes receiving every 16 weeks and 92.6% (137\/148; 90% CI, 88.0%-95.8%) of SRes receiving dosing every 8 weeks having PASI lower than 3 at W68. Clinical effects corresponded with immunologic changes; skin CD8-positive tissue-resident memory T (TRM)\u2013cell count decreased quickly from baseline, remaining low in both dosing groups. Similarly, serum IL-17A, IL-17F, IL-22, and \u03b2 defensin (BD)\u20132 levels decreased significantly from baseline, remaining low in both dosing groups to W68. Guselkumab was well-tolerated; no new safety signals were identified.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Psoriasis treatment guidelines lack or provide inconsistent advice on patient stratification and treatment de-escalation. We present the first randomized trial providing evidence that, in patients with early complete skin clearance at 2 consecutive visits (W20 and W28), extending the guselkumab dosing interval may control disease activity.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03818035<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.2463","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T13:14:47Z","timestamp":1722431687000},"page":"953","source":"Crossref","is-referenced-by-count":55,"title":["Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis"],"prefix":"10.1001","volume":"160","author":[{"given":"Kilian","family":"Eyerich","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khusru","family":"Asadullah","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin, Berlin, Germany"},{"name":"Dermatology Potsdam MVZ, Potsdam, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[{"name":"University Hospital Frankfurt am Main, Frankfurt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Weisenseel","sequence":"additional","affiliation":[{"name":"Dermatologikum Hamburg, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[{"name":"Translational Research in Inflammatory Skin Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carle","family":"Paul","sequence":"additional","affiliation":[{"name":"Toulouse University, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Sabat","sequence":"additional","affiliation":[{"name":"Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, and Institute of Medical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Wolk","sequence":"additional","affiliation":[{"name":"Psoriasis Research and Treatment Center, Department of Dermatology, Venereology and Allergology, and Institute of Medical Immunology, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin and Humboldt-Universit\u00e4t zu Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Eyerich","sequence":"additional","affiliation":[{"name":"Center for Allergy and Environment, Technical University and Helmholtz Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Lauffer","sequence":"additional","affiliation":[{"name":"Center for Allergy and Environment, Technical University and Helmholtz Center Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julianty","family":"Angsana","sequence":"additional","affiliation":[{"name":"Janssen R&D, LLC, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedemann J. H.","family":"Taut","sequence":"additional","affiliation":[{"name":"Taut Science and Service GmbH, Konstanz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Kohler","sequence":"additional","affiliation":[{"name":"Janssen R&D, LLC, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Chen","sequence":"additional","affiliation":[{"name":"Janssen R&D, LLC, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn","family":"Sendecki","sequence":"additional","affiliation":[{"name":"Janssen R&D, LLC, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica W. L.","family":"Leung","sequence":"additional","affiliation":[{"name":"Janssen R&D, LLC, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Wegner","sequence":"additional","affiliation":[{"name":"Janssen-Cilag GmbH, Neuss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Personke","sequence":"additional","affiliation":[{"name":"Janssen-Cilag GmbH, Neuss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Gomez","sequence":"additional","affiliation":[{"name":"Janssen Global Services LLC, Horsham, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenja","family":"Kr\u00fcger","sequence":"additional","affiliation":[{"name":"Janssen-Cilag GmbH, Neuss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tabori","sequence":"additional","affiliation":[{"name":"Janssen-Cilag GmbH, Neuss, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Sch\u00e4kel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, and Interdisciplinary Center for Inflammatory Diseases, Heidelberg University Hospital, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi240026r1","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis.","volume":"2","author":"Greb","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"10281","key":"doi240026r2","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis.","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"doi240026r3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1177\/24755303221127338","article-title":"Resident memory T cells in psoriasis: key to a cure?","volume":"7","author":"Blauvelt","year":"2022","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"9","key":"doi240026r4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049822","article-title":"IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE).","volume":"11","author":"Eyerich","year":"2021","journal-title":"BMJ Open"},{"key":"doi240026r5","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2154570","article-title":"National consensus on biologic dose reduction in psoriasis: a modified eDelphi procedure.","volume":"2154570","author":"van der Schoot","year":"2022","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"doi240026r6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi240026r7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10201","key":"doi240026r8","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"doi240026r9","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1111\/jdv.19236","article-title":"Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance (\u2018clinical super response\u2019): week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE study.","volume":"37","author":"Sch\u00e4kel","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"doi240026r11","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.jid.2021.01.005","article-title":"Differential changes in inflammatory mononuclear phagocyte and T-cell profiles within psoriatic skin during treatment with guselkumab vs. secukinumab.","volume":"141","author":"Mehta","year":"2021","journal-title":"J Invest Dermatol"},{"issue":"12","key":"doi240026r12","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.jid.2019.05.016","article-title":"Guselkumab efficacy after withdrawal is associated with suppression of serum IL-23-regulated IL-17 and IL-22 in psoriasis: VOYAGE 2 study.","volume":"139","author":"Gordon","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"9","key":"doi240026r13","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1038\/jid.2011.139","article-title":"Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin.","volume":"131","author":"Bovenschen","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi240026r14","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"doi240026r15","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/ddg.14508","article-title":"German S3-Guideline on the treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 1: treatment goals and treatment recommendations.","volume":"19","author":"Nast","year":"2021","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"doi240026r16","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR).","volume":"182","author":"Mahil","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi240026r17","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.jaci.2016.06.038","article-title":"\u00df-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis.","volume":"139","author":"Kolbinger","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"doi240026r18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/jcph.1063","article-title":"Population pharmacokinetic modeling of guselkumab, a human IgG1? monoclonal antibody targeting IL-23, in patients with moderate to severe plaque psoriasis.","volume":"58","author":"Yao","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"doi240026r19","doi-asserted-by":"publisher","first-page":"e424","DOI":"10.1111\/jdv.19652","article-title":"An international Delphi consensus to define a clinically appropriate definition of disease modification for plaque psoriasis.","volume":"38","author":"Eyerich","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"doi240026r20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/bjd.18143","article-title":"Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi240026r21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40265-020-01448-z","article-title":"Dose tapering of biologics in patients with psoriasis: a scoping review.","volume":"81","author":"Michielsens","year":"2021","journal-title":"Drugs"},{"issue":"6","key":"doi240026r22","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/bjd.15722","article-title":"Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR).","volume":"177","author":"Blauvelt","year":"2017","journal-title":"Br J Dermatol"},{"issue":"7","key":"doi240026r23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40261-023-01280-9","article-title":"Real-world performance of a new strategy for off-label use of guselkumab in moderate to severe psoriasis: super-responder patients as the epitome of efficacy and optimisation.","volume":"43","author":"Herranz-Pinto","year":"2023","journal-title":"Clin Drug Investig"},{"issue":"1","key":"doi240026r25","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jdermsci.2019.06.002","article-title":"Significance of IL-17A-producing CD8+CD103+ skin resident memory T cells in psoriasis lesion and their possible relationship to clinical course.","volume":"95","author":"Kurihara","year":"2019","journal-title":"J Dermatol Sci"},{"issue":"2","key":"doi240026r26","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1111\/bjd.17748","article-title":"CD8 resident memory T cells with interleukin 17A-producing potential are accumulated in disease-na\u00efve nonlesional sites of psoriasis possibly in correlation with disease duration.","volume":"181","author":"Vo","year":"2019","journal-title":"Br J Dermatol"},{"issue":"10275","key":"doi240026r27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"doi240026r28","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1111\/jdv.18474","article-title":"Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator\u2019s Global Assessment scores predict complete skin clearance.","volume":"36","author":"Reich","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"doi240026r10","author":"Liu","year":"2018"},{"key":"doi240026r24","author":"Kreuger","year":"2022"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2821677\/jamadermatology_eyerich_2024_oi_240026_1728397268.62533.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T11:27:26Z","timestamp":1728473246000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2821677"}},"subtitle":["The GUIDE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,9,1]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.2463","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9,1]]}}}